← ANALYST RATINGS · TIPRANKS
Prelude Therapeutics (PRLD): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $10.00, the highest $12.00, the lowest $8.00. The average is +206.7% from the last price of $3.26.
Analyst ratings 5
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −8.0% | Reiterated | 15.10.26on TipRanks 07:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −8.0% | Reiterated | 15.10.26on TipRanks 07:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Sell | −8.0% | Downgrade | 15.10.26on TipRanks 07:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −8.0% | Reiterated | 15.10.26on TipRanks 07:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 14.10.26on TipRanks 07:05 | — | |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $8.00 | Buy | +145.4% | Reiterated | 13.10.26on TipRanks 12:35 | −4.8%next day −8.2% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $4.00+14.3% | Hold | +22.7% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $4.00+14.3% | Hold | +22.7% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $4.00+14.3% | Hold | +22.7% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 03.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +7.4% | Reiterated | 02.10.26on TipRanks 02:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 | Hold | +22.7% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 | Hold | +22.7% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 | Hold | +22.7% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 | Hold | +22.7% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 | Hold | +22.7% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 | Hold | +22.7% | Reiterated | 01.10.26on TipRanks 01:05 | — | |
| Name not given | — | $12.00 | Buy | +268.1% | Initiated | 17.09.26on TipRanks 07:10 | +1.1%next day +6.4% · 5 days −13.5% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $8.00 | Buy | +145.4% | Reiterated | 29.07.26on TipRanks 06:39 | +3.0%next day +5.5% · 5 days −9.1% | ↗ |
| Jason Kolbert★★★★★★★★★★#12335 · hits 32% · avg −9.0% | D. Boral Capital | $9.00 | Buy | +176.1% | Initiated | 04.05.26on TipRanks 07:40 | +1.2%next day −2.3% · 5 days −1.7% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $3.00 → $6.00+100.0% | Buy | +84.0% | Reiterated | 11.03.26on TipRanks 05:20 | +6.0%next day −10.0% · 5 days −15.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Prelude Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.00 at a price of $3.91 (+155.8%); now: $10.00 at $3.26 (+206.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 3 | 2 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.01 (from $-0.16 to $0.63). Last quarter: $-0.14.
Sales
Next quarter’s sales estimate — $29M (from $5M to $100M). Last quarter: $6M.
Best top-analyst consensus in the sector · Healthcare
About Prelude Therapeutics
- CEO: Krishna Vaddi
- Employees: 79
- 175 Innovation Boulevard, Wilmington, DE, 19805, US
- www.preludetx.com
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Data from the stock’s TipRanks forecast page, read 50 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗